Mostrando 6 resultados de: 6
Filtros aplicados
Publisher
Biomedicine and Pharmacotherapy(1)
Cell and Bioscience(1)
Expert Opinion on Drug Discovery(1)
Journal of Alzheimer's Disease(1)
Neural Plasticity(1)
Origen
scopus(6)
Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice
ArticleAbstract: Background: Several studies stablished a relationship between metabolic disturbances and Alzheimer´sPalabras claves:Alzheimer´s disease, APPswe/PS1dE9, Cognitive deficits, Dexibuprofen, High fat diet, Metabolic alterations, neuroinflammation, synapsis, unfolded protein response, βA plaquesAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Carrasco M., Espinosa-Jimenez T., Ettcheto M., Folch J., Herrera K., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusCurrent Research Therapeutic Strategies for Alzheimer's Disease Treatment
ReviewAbstract: Alzheimer's disease (AD) currently presents one of the biggest healthcare issues in the developed coPalabras claves:Autores:Abad S., Antoni Camins, Auladell C., Ettcheto M., Folch J., García M.L., Olloquequi J., Petrov D., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusMemantine for the treatment of dementia: A review on its current and future applications
ReviewAbstract: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the presence in the brainPalabras claves:Alzheimer's disease, Amyloid-protein, Extrasynaptic N-Methyl-D-aspartate receptor, Memantine, Tau proteinAutores:Antoni Camins, Auladell C., Busquets O., Casadesús G., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Olloquequi J., Pelegrí Gabalda C., Sanchez-Lopez E., Verdaguer E., Vilaplana J., Zárate C.B.Fuentes:scopusMetformin a potential pharmacological strategy in late onset Alzheimer’s disease treatment
ReviewAbstract: Alzheimer’s disease (AD) is one of the most devastating brain disorders. Currently, there are no effPalabras claves:Alzheimer’s disease, AMP activated protein kinase AMPK, Beta amyloid, diabetes mellitus, Insulin Resistance, Metformin, Tau protein hyperphosphorylationAutores:Antoni Camins, Cano A., Ettcheto M., Javan M., Manzine P.R., Olloquequi J., Poor S.R., Sanchez-Lopez E.Fuentes:scopusProtein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders
ReviewAbstract: Protein tyrosine phosphatase 1B (PTP1B) is a typical member of the PTP family, considered a direct nPalabras claves:Alzheimer's disease, insulin receptor, neurodegenerative diseases, neuroinflammation, Neurological disorders, PTP1B, Type 2 DiabetesAutores:Antoni Camins, Auladell C., Bulló M., Cano A., Carrasco M., Ettcheto M., Folch J., Fortuna A., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusThe preclinical discovery and development of opicapone for the treatment of Parkinson’s disease
ArticleAbstract: Introduction: Opicapone (OPC) is a well-established catechol-O-methyltransferase (COMT) inhibitor thPalabras claves:dyskinesia, entacapone, Opicapone, Parkinson’s Disease, tolcaponeAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Ettcheto M., Folch J., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopus